Breast Cancer Clinical Trial

Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)

Summary

This is a Phase 1/2, first-in-human, open-label, dose escalation and dose-expansion study of E-602, administered alone and in combination with pembrolizumab.

View Full Description

Full Description

This study is being conducted to evaluate the safety, tolerability, PK, pharmacodynamics, and antitumor activity of E-602 in subjects with advanced cancers.

Phase 1 of the study consists of dose escalation cohorts of E-602 as a monotherapy and in combination with pembrolizumab. Dose escalation will utilize a modified 3+3 design. Any Phase 1 cohort may be backfilled, up to a total of 15 subjects to obtain additional safety, PK, and pharmacodynamic data at a particular dose level. Phase 1 will treat subjects with melanoma, ovarian cancer, non-small cell lung cancer (NSCLC), colorectal cancer, pancreatic cancer, breast cancer, gastric/esophagogastric junction (EGJ) cancer, head and neck cancer, or urothelial cancer. The safety and pharmacodynamic data will be evaluated to identify the maximum tolerated dose and recommended Phase 2 dose level for E-602 as monotherapy and in combination with pembrolizumab.

Phase 2 consists of dose-expansion disease cohorts in subjects with 3 types of advanced tumors: melanoma, NSCLC, and a third type to be determined (ovarian, colorectal, pancreatic, breast, gastric/EGJ, head and neck, or urothelial) based on available data. Phase 2 includes cohorts of E-602 as monotherapy and E-602 in combination with pembrolizumab. For each cohort in Phase 2, Simon's minimax 2-stage design will be used.

The study is seeking to enroll a total of up to 273 subjects (up to 87 in Phase 1 and up to 186 in Phase 2). Subjects will participate in the study for about 16 months.

View Eligibility Criteria

Eligibility Criteria

Key Inclusion Criteria:

Subjects with advanced or relapsed/refractory melanoma, ovarian cancer, NSCLC, colorectal cancer, pancreatic cancer, breast cancer, gastric/esophagogastric junction (EGJ) cancer, head and neck cancer, or urothelial cancer who have failed prior therapies.

a. Subjects with melanoma, NSCLC, head and neck cancer, urothelial cancer, or mMSI-H or dMMR colorectal cancer must have had prior anti-PD-(L)1 pathway therapy and been deemed resistant (had progression on therapy or within 3 months of discontinuation of therapy).

Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Subject has disease that is measurable by Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1.
Adequate bone marrow, coagulation, renal function, and liver function as determined by laboratory tests

Key Exclusion Criteria:

For cohorts receiving E-602 and pembrolizumab combination therapy:

Prior moderate or severe hypersensitivity to pembrolizumab or its formulation
History of severe autoimmune complications or discontinuation due to toxicity following treatment with an anti-PD-(L)1 pathway therapy.
Subject has an active autoimmune disease with the exception of auto-immune endocrinopathies that are stable on hormone replacement therapy.
Subject has a history of colitis.
History of age-related macular degeneration (AMD).
Recent surgery, treatment with another investigational agent, active infection, non-healing wound or uncontrolled bleeding/bleeding diathesis.
Received a vaccine or prior radiotherapy within 14 days prior to Cycle 1 Day 1.
Prior history of interstitial lung disease that required steroids or ≥ Grade 2 immune-related pneumonitis or has current non-infectious pneumonitis or interstitial lung disease.
Untreated brain metastases or another untreated primary malignancy
Subject is taking the equivalent of >10 mg/day oral prednisone or on systemic immunosuppressive therapy.
Subject has had an allogeneic tissue or organ transplantation.
History of thromboembolic event unless the event occurred > 6 months from Cycle 1 Day 1 and the subject is on anti-coagulation treatment.

Study is for people with:

Breast Cancer

Phase:

Phase 1

Estimated Enrollment:

273

Study ID:

NCT05259696

Recruitment Status:

Recruiting

Sponsor:

Palleon Pharmaceuticals, Inc.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 9 Locations for this study

See Locations Near You

University of Southern California
Los Angeles California, 90033, United States More Info
Xiomara Menendez, RN
Contact
[email protected]
Anthony El-Khoueiry, MD
Principal Investigator
Stanford Health Care
Stanford California, 94305, United States More Info
Debjani Ghoshal
Contact
650-725-5903
[email protected]
Chris Chen, MD
Principal Investigator
START Midwest
Grand Rapids Michigan, 49546, United States More Info
Julie Burns
Contact
616-954-5559
[email protected]
Manish Sharma, MD
Principal Investigator
Roswell Park Comprehensive Cancer Center
Buffalo New York, 14263, United States More Info
Paige Burkard
Contact
716-845-1127
[email protected]
Tong Dai, MD
Principal Investigator
Columbia University
New York New York, 10032, United States More Info
Brian Henick, MD
Principal Investigator
Providence Cancer Institute
Portland Oregon, 97213, United States More Info
Providence Cancer Institute
Contact
503-215-2614
[email protected]
Brendan Curti, MD
Principal Investigator
University of Pittsburgh Medical Center
Pittsburgh Pennsylvania, 15232, United States More Info
University of Pittsburgh Medical Center
Contact
[email protected]
Jason Luke, MD
Principal Investigator
Sarah Cannon Research Institute
Nashville Tennessee, 37203, United States More Info
Sarah Cannon Research Institute
Contact
[email protected]
Melissa Johnson, MD
Principal Investigator
NEXT Oncology
San Antonio Texas, 78229, United States More Info
Cynthia DeLeon
Contact
210-580-9500
[email protected]
Anthony Tolcher, MD
Principal Investigator

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Phase:

Phase 1

Estimated Enrollment:

273

Study ID:

NCT05259696

Recruitment Status:

Recruiting

Sponsor:


Palleon Pharmaceuticals, Inc.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.